Soleno Therapeutics (SLNO)
(Delayed Data from NSDQ)
$46.88 USD
-1.26 (-2.62%)
Updated Sep 24, 2024 04:00 PM ET
After-Market: $46.86 -0.02 (-0.04%) 7:58 PM ET
3-Hold of 5 3
C Value D Growth C Momentum D VGM
Balance Sheet
Fiscal Year End for Soleno Therapeutics, Inc falls in the month of December.
All items in Millions except Per Share data.
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 170 | 15 | 21 | 49 | 21 |
Receivables | 0 | 0 | 0 | 0 | 0 |
Notes Receivable | 0 | 0 | 0 | 0 | 0 |
Inventories | 0 | 0 | 0 | 0 | 0 |
Other Current Assets | 2 | 1 | 1 | 1 | 0 |
Total Current Assets | 171 | 16 | 22 | 50 | 21 |
Net Property & Equipment | 0 | 0 | 0 | 0 | 0 |
Investments & Advances | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Assets | 0 | 0 | 0 | 0 | 0 |
Deferred Charges | 0 | 0 | 0 | 0 | 0 |
Intangibles | 9 | 11 | 13 | 15 | 17 |
Deposits & Other Assets | 0 | 0 | 0 | 0 | 0 |
Total Assets | 181 | 27 | 36 | 65 | 38 |
Liabilities & Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Notes Payable | 0 | 0 | 0 | 0 | 0 |
Accounts Payable | 3 | 2 | 3 | 3 | 2 |
Current Portion Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Current Portion Capital Leases | 0 | 0 | 0 | 0 | 0 |
Accrued Expenses | 7 | 5 | 4 | 5 | 2 |
Income Taxes Payable | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 2 | 0 | 0 | 0 | 0 |
Total Current Liabilities | 12 | 7 | 8 | 9 | 5 |
Mortgages | 0 | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | 0 | 0 | 0 | 0 | 0 |
Convertible Debt | 0 | 0 | 0 | 0 | 0 |
Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Non-Current Capital Leases | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 12 | 9 | 10 | 11 | 18 |
Minority Interest (Liabilities) | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 23 | 16 | 18 | 19 | 23 |
Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Preferred Stock | 0 | 0 | 0 | 0 | 0 |
Common Stock (Par) | 0 | 0 | 0 | 0 | 0 |
Capital Surplus | 434 | 248 | 231 | 228 | 173 |
Retained Earnings | -276 | -237 | -213 | -182 | -158 |
Other Equity | 0 | 0 | 0 | 0 | 0 |
Treasury Stock | 0 | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | 158 | 10 | 18 | 46 | 15 |
Total Liabilities & Shareholder's Equity | 181 | 27 | 36 | 65 | 38 |
Total Common Equity | 158 | 10 | 18 | 46 | 15 |
Shares Outstanding | 30.50 | 8.10 | 5.30 | 5.30 | 2.90 |
Book Value Per Share | 5.16 | 1.28 | 3.36 | 8.59 | 5.16 |
Fiscal Year End for Soleno Therapeutics, Inc falls in the month of December.
All items in Millions except Per Share data.
6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 266 | 150 | 170 | 52 | 19 |
Receivables | 0 | 0 | 0 | 0 | 0 |
Notes Receivable | 0 | 0 | 0 | 0 | 0 |
Inventories | 0 | 0 | 0 | 0 | 0 |
Other Current Assets | 1 | 2 | 2 | 1 | 1 |
Total Current Assets | 268 | 151 | 171 | 54 | 21 |
Net Property & Equipment | 0 | 0 | 0 | 0 | 0 |
Investments & Advances | 28 | 9 | 0 | 0 | 0 |
Other Non-Current Assets | 0 | 0 | 0 | 0 | 0 |
Deferred Charges | 0 | 0 | 0 | 0 | 0 |
Intangibles | 8 | 8 | 9 | 9 | 10 |
Deposits & Other Assets | 0 | 0 | 0 | 0 | 0 |
Total Assets | 304 | 169 | 181 | 64 | 31 |
Liabilities & Shareholders Equity | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 |
---|---|---|---|---|---|
Notes Payable | 0 | 0 | 0 | 0 | 0 |
Accounts Payable | 4 | 8 | 3 | 3 | 3 |
Current Portion Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Current Portion Capital Leases | 0 | 0 | 0 | 0 | 0 |
Accrued Expenses | 4 | 4 | 7 | 5 | 5 |
Income Taxes Payable | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 1 | 2 | 2 | 21 | 1 |
Total Current Liabilities | 9 | 13 | 12 | 29 | 9 |
Mortgages | 0 | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | 0 | 0 | 0 | 0 | 0 |
Convertible Debt | 0 | 0 | 0 | 0 | 0 |
Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Non-Current Capital Leases | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 14 | 12 | 11 | 9 | |
Minority Interest (Liabilities) | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 23 | 25 | 23 | 40 | 19 |
Shareholders Equity | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 |
---|---|---|---|---|---|
Preferred Stock | 0 | 0 | 0 | 0 | 0 |
Common Stock (Par) | 0 | 0 | 0 | 0 | 0 |
Capital Surplus | 601 | 441 | 434 | 288 | 267 |
Retained Earnings | -320 | -298 | -276 | -265 | -254 |
Other Equity | 0 | 0 | 0 | 0 | 0 |
Treasury Stock | 0 | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | 281 | 143 | 158 | 23 | 12 |
Total Liabilities & Shareholder's Equity | 304 | 169 | 181 | 64 | 31 |
Total Common Equity | 281 | 143 | 158 | 23 | 12 |
Shares Outstanding | 33.40 | 33.40 | 30.50 | 15.40 | 8.10 |
Book Value Per Share | 8.41 | 4.29 | 5.16 | 1.51 | 1.53 |